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The Year in Congenital Heart Disease
The review by Graham (1) is an excellent and welcome summary
of surgical, interventional, and medical progress in congenital heart
disease. There are sufficient data to allow the reader to form an
opinion, backed up by specific references, as well as useful critical
remarks of consensus.
I was particularly interested in his comments about postopera-
tive pulmonic insufficiency in patients with tetralogy who are now
being recognized as a significant problem in a growing population
of postoperative adults. Initially, we all had hoped that pulmonic
insufficiency would not be a problem, and surgeons were urged to
abolish completely any gradient across the right ventricular (RV)
outflow tract because of concerns that if the RV pressure was still
elevated it would create a risk for arrhythmias, and even sudden
death. As these youngsters lived with their insufficiency, they
developed large right ventricles, but were generally asymptomatic.
This tolerance of volume overload is also characteristic of the left
ventricle, but in their teens and twenties those young patients are
beginning to need valve replacements. Unfortunately, we do not
have the same reliable guidelines (ejection fraction) for the right
ventricle as we have for the left.
Although we will have to face difficult decisions for our current
generation of postoperative tetralogy patients with severe pulmonic
insufficiency—considering the limited half-life for biological valve
replacements, as Graham (1) mentioned—shouldn’t we revisit the
degree of insufficiency being created in today’s infants and chil-
dren? Many years ago one of the pioneers of surgical correction of
tetralogies anticipated the problem: Frank Gerbode (personal
communication, June 1965) warned that it would be better
physiologically to leave a moderate degree of pulmonic stenosis
rather than create severe pulmonic insufficiency. He reasoned that
the less compliant right ventricle associated with moderate stenosis
would resist the insufficiency, and that moderate stenosis would be
better tolerated.
As a minimum, we should review the evidence as to whether we
have unnecessarily accepted all the problems of severe pulmonic
replacement absent a test of the alternate approach of moderation
in disabling the valve at surgery.
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It is a pleasure to respond to Dr. Guntheroth’s comments regard-
ing my paper (1) and the current state of affairs for patients with
tetralogy of Fallot and significant postoperative pulmonary insuf-
ficiency. As he clearly states, many of these adult patients have an
enlarged right ventricle that can show a progressive decrease in
ventricular function, which at some point becomes partially or
completely irreversible. In addition, patients with a marked degree
of right ventricular (RV) enlargement and decreased function
appear to be potentially more susceptible to significant arrhyth-
mias, which, on rare occasions, can be life-threatening. The
optimal treatment for these patients is theoretically available with
pulmonary valve replacement, which can be performed with low
mortality and morbidity. When this procedure is done early
enough in the course of the inexorable decrease of RV function,
there is a decrease in RV size (usually modest) and improvement in
RV function and exercise ability. Unfortunately, valves that have
been used in the pulmonary position have, under most circum-
stances, shown a half-life of only 10 to 12 years. The newer, larger
bio-prosthetic pericardial valves have shown some promise for
holding on longer, but the data are not complete on these valves to
make that a clear-cut alternative with promise for a longer interval
between reoperations.
The search for an optimal bio-prosthetic valve (one that can be
grown from one’s blood cells outside the body and then re-
implanted and possibly delivered with a catheter-interventional
technique) is the hope of the future.
In the interim, I agree with Dr. Guntheroth that we should
continue to revisit the issue of leaving mild pulmonary stenosis
rather than create severe pulmonary insufficiency. This can be a
difficult management decision in the operating room as the more
severe tetralogy patients with severe outflow obstruction and small
main pulmonary arteries are not amenable to successful repair
without leaving them with significant pulmonary insufficiency.
Moreover, when one has to do a significant ventriculotomy and
leave moderate stenosis, right ventricle dysfunction can occur early
in the postoperative period and be even more severe than that
associated with moderate/severe pulmonary insufficiency.
During follow-up visits, postoperative tetralogy patients, most
of whom have had an excellent overall outcome long term,
continue to need attention to their RV size and function and to the
potential for rhythm disorder; this should be done by physicians
with expertise in both adult cardiology and congenital heart
disease. Magnetic resonance imaging of the right ventricle with
quantification of RV volumes and ejection fraction as well as
exercise testing with maximum VO2 measurement can be quite
useful in terms of serial assessment and consideration for interven-
tion. There is a growing need for training the next generation of
physicians who can provide optimal care for this burgeoning group
of adults with congenital heart disease.
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Defibrillation Thresholds
Testing of Implantable
Cardioverter-Defibrillators at Implantation
I read with interest the reports on defibrillation testing (DFT)
during implantable cardioverter-defibrillator (ICD) implantation
published recently in JACC (1,2). There is a significant, albeit low,
risk to serious complications including death during DFT testing.
If the implantation data as measured through the device are
satisfactory, then should we induce ventricular fibrillation (VF) in
a patient who has poor cardiac function? Should we crash a brand
new car during its “test-drive” to see whether the airbags will
deploy? The following cases, which are mere examples, demon-
strate the professional and moral dilemma of DFT testing.
Two patients with severe cardiomyopathy underwent ICD
implantation with excellent parameters. In the first case, during
DFT testing, first shock to provide a 10-J safety margin and a
subsequent maximum output shock failed to defibrillate. External
defibrillation restored sinus rhythm but with severe electrome-
chanical dysfunction requiring emergent placement of a ventricular
assist device and subsequently a heart transplantation. Was car-
diomyopathy in itself responsible for the ICD failure? Did the
shocks cause electromechanical dysfunction? Could the patient
have survived an out-of-hospital VF episode? Did DFT testing
identify deficiencies at implant? In the second case, DFT testing
was not performed because of the presence of atrial fibrillation,
suboptimal anticoagulation profile, and evidence of sludge in the
left atrial appendage by a transesophageal echocardiogram. Elec-
tive cardioversion and DFT testing after six weeks of anticoagu-
lation was planned. Unfortunately, in the interim period, the
patient met with an unnatural mode of death. Subsequently, the
patient’s wife reported that “it may not mean much . . . but the
defibrillator did go off . . . many times . . . it did work . . . when my
husband died. . . .”
During automobile accidents the airbags drastically reduce
morbidity and mortality, but there is also a spectrum of injuries
associated with them (3,4). Taking the analogy of the airbags and the
ICDs, both of which reduce fatalities, perhaps in the case of the first
patient, the “airbag” in itself was not adequate to prevent the fatality
and, if anything, perhaps caused “airbag”-associated injuries. In the
case of the second patient, the “airbag” deployed appropriately but
could not prevent a non-road-traffic-crash–related fatality.
Needless to say, until improvements in science and technology
provide conclusive evidence that the ICDs effectively and predictably
provide life-saving therapy without actually testing them at the time of
implantation, the dilemma of DFT testing will remain unsolved.
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I thank Dr. Kantharia for his interest in our recent paper (1).
Identifying the optimal patient-specific implantable cardioverter-
defibrillator (ICD) system and its programming, without the need
for either ventricular fibrillation (VF) or shocks, is a major research
goal. The patients reported by Dr. Kantharia both emphasize the
importance of this goal and illustrate poignantly that it remains
beyond our grasp.
The first case highlights the unmet need of developing effective
treatment for life-threatening, post-VF electromechanical dys-
function (EMD) (2,3). Paradoxically, defibrillation testing may
have saved this patient’s life: If VF had occurred as an outpatient,
either defibrillation would have failed or the postshock rhythm
would have been lethal EMD. To the best of my knowledge, fatal
postshock EMD has not been reported after an inappropriate
shock. Thus, postshock EMD probably is caused by a combination
of VF and shocks, often prolonged VF and multiple shocks.
The second patient died from failed defibrillation with an
untested ICD system. This case illuminates the need for a
shockless method of assessing ventricular defibrillation efficacy, or
at least a method that minimizes the risk of thromboembolism
from atrial cardioversion. One consideration is continuous rapid
atrial stimulation during ventricular defibrillation or vulnerability
testing.
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